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Abstract
Given the important roles of miRNA in post-transcriptional regulation and its implications for cancer, characterization of
miRNA facilitates us to uncover molecular mechanisms underlying the progression of androgen-independent prostate
cancer (PCa). The emergence of next-generation sequencing technologies has dramatically changed the speed of all aspects
of sequencing in a rapid and cost-effective fashion, which can permit an unbiased, quantitive and in-depth investigation of
small RNA transcriptome. In this study, we used high-throughput Illumina sequencing to comprehensively represent the full
complement of individual small RNA and to characterize miRNA expression profiles in both the androgen dependent and
independent Pca cell line. At least 83 miRNAs are significantly differentially expressed, of which 41 are up-regulated and 42
are down-regulated, indicating these miRNAs may be involved in the transition of LNCaP to an androgen-independent
phenotype. In addition, we have identified 43 novel miRNAs from the androgen dependent and independent PCa library
and 3 of them are specific to the androgen-independent PCa. Function annotation of target genes indicated that most of
these differentially expressed miRNAs tend to target genes involved in signal transduction and cell communication, epically
the MAPK signaling pathway. The small RNA transcriptomes obtained in this study provide considerable insights into a
better understanding of the expression and function of small RNAs in the development of androgen-independent prostate
cancer.
Citation: Xu G, Wu J, Zhou L, Chen B, Sun Z, et al. (2010) Characterization of the Small RNA Transcriptomes of Androgen Dependent and Independent Prostate
Cancer Cell Line by Deep Sequencing. PLoS ONE 5(11): e15519. doi:10.1371/journal.pone.0015519
Editor: Patrick Ling, Queensland University of Technology, Australia
Received August 1, 2010; Accepted October 6, 2010; Published November 30, 2010
Copyright:  2010 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Zhejiang Provincial Natural Science Foundation of China (No. Y2100902), Wenzhou Science and Technology Project
(Y20100011), Zhejiang Provincial Science and Technology Platform of Analysis and Testing Technology Projects (2009F82G2090045) and National High
Technology Research and Development Program of China (2006AA02A304). The funders had no role in study design, data collection and analysis, decisiont o
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wwwtzh@wz.zj.cn (ZT); fuz3@psu.edu (FZ); sunzs@psych.ac.cn (ZS)
. These authors contributed equally to this work.
Introduction
Prostate cancer (PCa) is the most common malignancy of the
male genitourinary tract and the third leading cause of cancer
death [1,2]. As PCa growth is initially dependent on androgens for
survival, androgen deprivation therapy (ADT) has been the
mainstay of treatment for PCa. However, these tumors will
eventually progress to an androgen-independent phenotype and
fail to respond to ADT treatment, becoming the major obstacle of
clinical therapy. Understanding the molecular mechanisms that
underlie the progression of androgen-independent PCa will shed
considerable lights on possible treatment strategies for PCa.
miRNAs (microRNAs) are small, non-coding RNA (,20–22
nucleotides) that negatively regulate gene expression at the post-
transcriptional level [3]. Accumulating evidences indicate that
miRNAs may function as tumor suppressors and oncogenes [4,5].
Given the important roles of miRNAs in post-transcriptional
regulation, identification of these differentially expressed and novel
miRNAs will facilitate us to uncover the molecular mechanisms
underlying the progression of androgen-independent prostate
cancer.
To characterize the small RNA transcriptome, the new ‘deep-
sequencing’ technologies, such as Roche 454 and Illumina Solexa,
have been employed which have significant advantages over
previous hybridization-based methodologies, such as microarray
and PCR-based assays [6,7]. Firstly, it provides a more integrated
view of the miRNAs transcriptome. High-throughput sequencing
has the ability to identify modest or even low abundant miRNAs
exhibiting expression differences between distinct samples, to an
extent that previously could not be effectively detected. Secondly,
direct sequencing also offers the potential to detect the length
variation of mature miRNA and possible enzymatic modifications.
Thirdly, high-throughput sequencing allows the successful discov-
ery of novel miRNAs, which need not rely on querying candidate
regions of the genome but rather can be achieved by direct
observation and validation of the folding potential of flanking
genomic sequence. Taken together, next-generation sequencing
technologies offer a highly robust, accurate and scalable system
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investigation of miRNA transcriptome.
Till now, there are six genome-wide miRNA expression studies
in prostate cancer as reviewed by Gandellini et al. [8]. The first
miRNA expression profiling of prostate cancer was performed by
Lu and colleagues [5], in which they used a bead-based flow
cytometric technique to evaluate the miRNA profiling in different
tumor types. The remaining five studies applied microarray or
bead-based hybridization method to investigate miRNA expres-
sion signatures in prostate cancer compared with normal tissue,
and identified a number of aberrant expressed miRNAs in tumor
cells. However, these studies only focused on the comparison of
miRNA expression profiles between PCa samples and surrounding
non-tumor tissues, while not revealing what kinds of miRNA
might be correlated with the transition from androgen-sensitive to
androgen-independent in prostate cancer. Most recently, Sun
et al. found that several miRNAs, in particular miR-221 and miR-
222, were significantly over-expressed in androgen-independent
prostate cancer cells compared with those in the androgen-
dependent cell line, and implied the involvement of both miRNAs
in the development and progression of the androgen-indepen-
dence of prostate cancer [9]. deVere White et al. (2009) identified
a small set of miRNAs were aberrantly expressed in androgen-
independent PCa cell lines using microarray technology [10]. A
detailed comparison of miRNA expression profiles between the
androgen-dependent and androgen-independent cancers may
uncover how the miRNA pathway is involved in the progression
of prostate cancer to androgen independence. Using the next-
generation sequencing, we have obtained miRNA expression
signatures in androgen-independent prostate cancer and identified
83 miRNAs differentially expressed in LNCaP-AI cell lines, as well
as putative targets for these miRNAs. To our knowledge, this study
represents the first example of small RNA transcriptome by high-
throughput sequencing in the prostate cancer and has demon-
strated that deep sequencing can serve as an ideal, rapid and cost-
effective platform for characterization of small RNA expression
profiles.
Materials and Methods
Cell Culture
The androgen-dependent LNCaP cell line was obtained from
American Type Culture Collection (Rockville, MD) and was
routinely maintained in a regular medium: phenol red-positive F-
12 medium (Gibco) with 10% FBS (Biowest) at 37uCi n5 %C O 2.
Cells were fed twice per week and split once per week with
trypsinization (defined as one passage). To establish an androgen-
independent cell line, LNCaP was first maintained in phenol red-
free DMEM/F-12 medium (Gibco) with 10% charcoal/dextran-
treated FBS (Biowest). After cultured for 5 weeks, cells were
transferred to the above medium with 1.0610
27 mol/L flutamide
(Schering Plough) and cultured for another 105 passages.
Cell Proliferation Assay
Cells were seeded at a density of 3610
3 cells/well in a 96-well
culture plate in 90 ml regular media. After 24 hours of incubation
at 37uCi n5 %C O 2, the culture medium was changed with half of
the wells receiving regular medium and half receiving androgen
free medium (phenol red-free medium with 5.0610
26 mol/L
flutamide). The cells were incubated in 5% CO2 at 37uC for
72 hours, 10 ml of CCK-8 solution (Dojindo) was added to each
well, followed by incubation for 3 hours at 37uC, and the
absorbance was finally determined at 450 nm using microplate
reader (Bio-Rad).
Western blotting was carried out by the methods described
previously [11]. The following antibodies were used: rabbit anti-
Bcl-2 (1:200, Cell Signaling), rabbit anti-Bax (1:100, Cell
Signaling) and mouse anti-b-actin (1:1000, Cell Signaling).
Cell Cycle Assay
Cells were suspended in hormone-free and regular medium,re-
spectively, and were then planted in three 24-well plates with a
number of 3.3610
5 cells per well. After incubation in 5% CO2 at
37uC for 24 hours, flutamide was added into the holes. The cells
were harvested after incubating in 5% CO2 at 37uC for 72 hours.
The pretreatment procedure of cell cycle analysis was following the
manual of Cycle Test
plusDNA Reagent Kit (Becton Dickinson). Cell
cycle analysis was performed using a FACScan flow cytometer (BD
Company).
Real-time RT-PCR
Small RNAs (,200 nt) were isolated with mirVana
TM PARIS
TM
Kit (Ambion) according to the manufacturer’s instructions. For
RT reactions, 1 mg of small RNA was used for reverse
transcription with miScript Reverse Transcription Kit (Qiagen),
performed at 37uC for 60 min and a final incubation at 95uC for
5 min. MiRNA real-time RT-PCR was carried out by using the
miScript SYBR Green PCR kit (Qiagen) on an Applied
Biosystems 7000 real-time PCR machine (ABI). The PCR reaction
was conducted at 95uC for 15 min, followed by 40 cycles of
incubation at 94uC for 15 s, 55uC for 30 s, and 70uC for 30 s.
Each PCR was repeated at least three times. The relative
expression level of each miRNA was normalized by against U6
snRNA levels. Fold-change was calculated according to the
2
2DDCt method.
Small RNA Library Construction and High-throughput
Sequencing
The isolated total RNA was size-fractionated on a 15% tris-borate-
EDTA (TBE) urea polyacrylamide gel to enrich for molecules of 15–
30 nt. The small RNA was ligated with 39 (59-pUCGUAUGCCGU-
CUUCUGCUUGidT-39)a n d5 9 (59-GUUCAGAGUUCUACA-
GUCCGACGAUC-39) adapters using T4 RNA ligase and was again
size-fractionated ona 15%TBE urea polyacrylamide gel.The resulting
RNA was reversely transcribed to cDNA with Solexa’s small RNA
RT-Primer (59-CAAGCAGAAGACGGCATACGA-39). The cDNA
was used as a template for PCR amplification using Solexa’s small
RNAprimerset(59-CAAGCAGAAGACGGCATACGA-39;59-AAT-
GATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTC-
CGA-39). Finally, approximately 20 mgo fs m a l lR N Aw e r eu s e df o r
sequencing using Illumina 1 G Genome Analyzer according to the
manufacturer’s protocols.
Read Filter and Small RNA Annotation
For deep-sequencing reads produced by Illumina Genome
Analyzer, low quality reads were filtered out to exclude those most
likely to represent sequencing errors and 3/59 adaptor sequences
were subsequently trimmed into clean full length reads formatted
into a non-redundant Fasta format. The occurrences of eachunique
sequence reads were counted as sequence tags (the number of reads
for each tag reflects relative expression level) and only small RNA
sequences of 18 to 30 nt were retained for further analysis.
All unique sequence tags that pass above filters were mapped
onto the reference human genome using the SOAP 2.0 program
with at most two mismatches [12]. Subsequently, the unique
sequence tags were aligned against miRBase14.0, computationally
predicted human ncRNAs and Rfam 9.1 (http://rfam.sanger.ac.
The Small RNA Transcriptomes of Prostate Cancer
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www.girinst.org/), the human genes UCSC annotation hg18
(http://genome.ucsc.edu/) to classify known miRNA, degradation
fragments of non-coding RNA, genomic repeats and mRNA,
respectively. Sequences that did not overlap with any of these
annotations but could be aligned to the reference genome were
termed ‘‘unclassified’’.
Differential Expression Detection and Novel miRNA
Prediction
To compare differentially expressed miRNAs between LNCaP
and LNCaP-AI, read counts of each identified miRNAs was
normalized to the total number of miRNA reads. The statistical
significance (P-value) was inferred based on the Bayesian method,
which was developed for analysis of digital gene expression profiles
and could account for the sampling variability of tags with low
counts [13]. A specific miRNA was deemed to be significantly
differentially expressed if the P value given by this method was
#0.001 and there was at least a 2-fold change in normalized
sequence counts. The target genes for each differentially expressed
miRNA were predicted using TargetScan (http://www.targetscan.
org/), miRanda (http://www.microrna.org/), PicTar (http://
pictar.mdc-berlin.de/) and RNAhybrid (http://bibiserv.techfak.
uni-bielefeld.de/rnahybrid/). Given that miRNA targets predic-
tion often suffer from high level of false positives, only the target
gene supported by at least three independent tools were taken into
account. The Gene Ontology (GO) terms and KEGG pathways of
targeted genes were annotated using the DAVID gene annotation
tool (http://david.abcc.ncifcrf.gov/UTH).
The unannotated sequences that could be mapped to the
human genome were considered for detecting candidate novel
miRNA genes. In brief, 100 nucleotides of genomic sequence
flanking each side of these sequences were extracted and the RNA
secondary structures were predicted using RNAfold (http://rna.
tbi.univie.ac.at/cgi-bin/RNAfold.cgi). Candidate novel miRNA
was identified using MIREAP under default settings, which has
been widely adopted in related studies [14,15].
All sequencing data along with annotation results can be
available at http://59.79.168.90/pca.
Results
Establishment of an Androgen-independent LNCaP Cell
Line
Based upon the reports that androgen sensitive LNCaP cells
(Fig. 1A) can be converted to androgen-independent cells [16,17],
we attempted to generate an androgen-independent cell line by
continuously culturing of LNCaP cells in vitro. After three weeks
culture initiation in hormone-deprived medium, the proliferation
of the cells gradually slow down and a considerable number of cells
(about 40–50%) underwent apoptosis (Fig. 1B). The remaining
ones changed in morphology to display a neuroendocrine-like
phenotype (Fig. 1B). With increasing passage number, the cells
appeared with obvious morphological variations and become small
and flat, developing the ability to grow in an androgen-
independent fashion (a phenotype that we designated as
LNCaP-AI) (Fig. 1C). To estimate the effects of androgen-free
environment on LNCaP-AI cells growth, we continuously
examined the cell proliferation rate of the cell line at different
passages. It is shown that cell growth rate of LNCaP-AI cells was
shown a gradual downtrend from passage 1, 2, 5, 10 to 20,
however, as the passage number increased, cell proliferation rate
was increased gradually and almost reached to 100% (Fig. 1D).
After 110 passages during 2 years of culture, cell growth was
stabilized and can grow well in androgen-depleted environment.
To further prove that the LNCaP-AI cells have acquired the
ability to adapt to the hormone-free environment, more studies are
needed for insights into the effects of flutamide or androgen-free
environment on the cell cycle of LNCaP cells by flow cytometry,
and the androgen-dependent LNCaP cells were included as a
control. As expected, flutamide or androgen-free environment had
no significant effect on cell cycle distribution in the LNCaP-AI cells
(Fig. 1E). In contrast, this treatment in the LNCaP cells was induced
anaccumulationofcellsinthe G0/G1phaseandaccompaniedwith
a decrease in the S phase, and the inhibition effect was much
strongerwhenboth ofthemwerecombined(Fig.1F).Previousstudy
has revealed that Bcl-2 is overexpressed in the progression to
androgen-refractory prostate cancer [1]. To characterize the
expression of both Bcl-2 and Bax (Bcl-2–associated X protein)
proteins in the two cell lines (LNCaP and LNCaP-AI), Western
blotting analysis was performed (Fig. 1G). We found an increased
expression of Bcl-2 protein in LNCaP-AI cells in comparison with
LNCaP cells. Meanwhile, LNCaP cells expressed a similar level of
Bax protein. These results suggest that LNCaP-AI cells gained an
enhanced anti-apoptotic activity. Based on the above observations,
we have successfully established an androgen-independent LNCaP
cell line through long-term culture of LNCaP cells.
Small RNA Transcriptomes and Annotation
To investigate small RNA transcriptomes, Illumina high-
throughput sequencing technology was employed to both LNCaP
and LNCaP-AI small RNA libraries. Initially, a total of 9,107,833
and 10,083,251 raw sequence reads were produced for LNCaP
and LNCaP-AI, respectively. After filter and trimming of the reads
with low quality and adaptor, 3,978,524 and 4,734,866 sequence
reads were obtained corresponding to 302,325 (LNCaP) and
416,924 (LNCaP-AI) unique tags. Observation the length
distribution of small RNAs, we found that the majority of them
from the both libraries were 22 nt in size (Fig. 2A), which is
consistent with the typical size of miRNA from Dicer digestion
products. Meanwhile, there were a high percentage of identical
sequence tags (88.90%) between LNCaP and LNCaP-AI. These
results indicated that miRNAs have been successively enriched
from both libraries.
Subsequently, the 18–30 nt sequences from both libraries were
selected to map to the human genome, and a total of 3,747,159
(94.18%) and 4,433,423 (93.63%) sequences were detected to
match the genome with at most two mismatches, respectively
(Fig. 2B). Based on human genome annotations and a number of
well-characterized RNA databases (see Materials and Methods),
these small RNA sequences were annotated as known miRNA,
degradation fragments of non-coding RNA (tRNA, rRNA,
snRNA/snoRNA et al.), genomic repeat, mRNA or unclassified.
As expected, the most abundant RNA category from both libraries
was known miRNAs: 65.22% for LNCaP and 62.33% for LNCaP-
AI. The remaining less abundant categories were non-coding
RNA and genomic repeats. In addition, a small proportion of
reads could be mapped to coding sequences, which are likely to be
RNA degradation products. Accumulating evidence indicated that
some genomes can also transcribe short functional non-coding
transcripts, such as endogenous small interfering RNAs or repeat-
associated interfering RNAs, which has been characterized to
regulate of retrotransposition repression [18]. For example, it is
revealed that L1 retrotransposition is suppressed by endogenously
encoded small interfering RNAs in human cultured cells. Thus, it
is noteworthy that these small RNAs may also contain important
biological function that deserves further attention.
The Small RNA Transcriptomes of Prostate Cancer
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LNCaP-AI
Based on miRBase, 360 miRNAs (285 miRNAs and 75
miRNAs*) and 380 miRNAs (282 miRNAs and 98 miRNAs*)
were detected in LNCaP and LNCaP-AI, respectively (Table S1).
First, we found that different miRNAs exhibited significantly
different expression levels as measured by the frequency of read
counts, indicating a remarkable functional divergence of these
miRNAs. In LNCaP-AI, for example, about 8.99% of miRNAs and
miRNA*s are at high read counts (.1000), among which the hsa-
let-7 family (hsa-let-7c, hsa-let-7f, hsa-let-7a, hsa-let-7d, hsa-let-7b
and hsa-let-7e) is one of the most abundant miRNAs in our data set,
contributing .8.94% of the total miRNA reads. miRNA count
within the ranges of intermediate 100–1000 reads were up to 17.4%
and the remaining miRNA counts for approximately 73.7%.
The relative count of sequencing reads could be used to quantify
miRNA expression levels between LNCaP and LNCaP-AI. Based
on the normalized number of reads per sample (specifc miRNA/
total sequencing tags in the library), the majority of miRNAs (256)
were expressed approximately equally between the two libraries.
However, 83 of them were identified to be differentially expressed
with a fold changes .2.0 and P-value ,0.001 (Table 1, Fig. 3A
Figure 1. Changes in the biological characteristics of LNCaP cell line from androgen-dependent to androgen-independent. (A) The
morphology of parental LNCaP cells, which were cultured in regular medium for 3 days. (B) Neuroendocrine phenotype of LNCaP cells. LNCaP cells
were maintained in androgen-depleted medium and cultured for 3 passages. (C) Morphology of LNCaP-AI cells. LNCaP cells were cultured with
flutamide in androgen-depleted medium for 110 passages. (D) The cell growth rates of androgen-depleted cultured LNCaP cells at different passages
when grown in androgen deprivation environment. (E–F) The effects of androgen-depleted environment and flutamide on LNCaP-AI (E) and LNCaP-
FGC (F) cell cycle. (AI: androgen-depleted medium; Flu: 1.0610
27 mol/L of flutamide; norm: regular medium). (G) Bcl-2 and Bax expression in LNCaP
and LNCaP-AI cells.
doi:10.1371/journal.pone.0015519.g001
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down-regulated. To further validate these differentially expressed
miRNAs, 29 individual miRNAs were selected to perform
quantitative RT-PCR assay from independent biological repli-
cates. These 29 selected miRNAs covered both highly expressed
miRNAs (miR-222, miR-30a*, miR-100, miR-10b, miR-148b,
miR-1323, miR-221, miR-7, miR-223, miR-374b, miR-486-5p,
miR-7a*, miR-125b-2, miR-27a and miR-423-5) and lower
expressed miRNAs (miR-15b, miR-21, miR-17, miR-28-5p,
miR-532-3p, miR-200c, miR-93, miR-96, miR-200b*, miR-331-
3p, miR-200b, miR-106a, miR-301b and miR-301a). As shown in
Fig. 3B, a strong correlation (Pearson’s correlation =0.91) was
revealed between the Illumina deep sequencing data and the
quantitative RT-PCR measurements, indicating the robustness of
deep sequencing based expression analysis.
Novel miRNA Genes
One of the most important advantages for high-throughput
sequencing of small RNA transcriptome is that it allows to
discovery of potential novel miRNAs. To identify candidate novel
miRNAs in LNCaP and LNCaP-AI, we first filtered out Illumina
sequence tags that have been classified into annotated categories,
such as known miRNAs, non-coding RNA, genomic repeats or
coding sequences. We found that 235,058 and 259,454 of the
small RNA sequence tags in LNCaP and LNCaP-AI, respectively,
were derived from unannotated regions of the human genome.
These unclassified tags along with 100-bp flanking sequences were
analyzed by MIREAP, a sophisticated tool commonly used to
identify novel miRNAs from high-throughput sequencing data
[14,15]. In this way, we identified 43 putative novel miRNAs from
both libraries (Table 2 and Table S2): 22 in LNCaP and 31 in
LNCaP-AI (Table 2 and Table S2), and only 10 of them are
shared by both libraries.
We also observed that these 43 miRNAs have a size range of
20–24 nt and the lengths of their predicted hairpin structures vary
from 65–98 nt, which is similar to known human miRNAs (Table
S2). The minimum free energies of their precursors range from
218.20 to 267.40 kcal/mol with the average value of 252.70
kcal/mol. To further validate these novel miRNAs, we performed
real-time RT-PCR analysis on all of 10 novel miRNA candidates
Figure 2. Size distribution and annotation of small RNAs from the libraries of LNCaP and LNCaP-AI. (A) Length distribution of
sequenced reads. Both libraries accumulated 22-nucleotide small RNAs, which is consistent with the typical size of miRNAs. B) The proportions of
various classes of small RNAs detected in LNCaP and LNCaP-AI. It is indicated that the majority of reads in both libraries belonging to the miRNA
families.
doi:10.1371/journal.pone.0015519.g002
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were excluded in view of their low expression level and the
sensitivity of real-time RT-PCR analysis). As a result, we have
successfully validated eight of them (Table 2), indicating that 80%
could be validated by a sequencing-independent method.
In comparison with other miRNAs in our study, these novel
miRNAs have a much lower expression level with an average
normalized sequencing frequency of 45, indicating that the
majority of them may not exhibit significant functions in prostate
cancer. Among them, three LNCaP-AI specific miRNAs exhibited
relative sequence counts large than 10 and validated by real-time
RT-PCR, implicating their likely involvement in the development
of LNCaP-AI, and thus deserve further functional evaluation.
Predicted Targets of Differentially Expressed miRNAs
To explore the biologic function of the differentially expressed
miRNAs identified in our analysis, we performed computational
analysis using four independent algorithms, including TargetScan,
miRanda, RNAhybrid and PicTar, for identification of predicted
messenger RNA targets for each miRNA to be significantly
differentially expressed. Table S3 lists predicted targets that were
supported by at least three of the above four algorithms, in which a
total of 6902 genes were potential targets of these miRNAs.
Interestingly, among these predicted targets, AKT3 was involved in
11 significantly down-expressed miRNAs. AKT3 encodes a
member of serine/threonine protein kinase family, which is known
to be involved in a wide variety of biological processes including cell
proliferation, differentiation, apoptosis, and tumorigenesis. The up-
expression of AKT3 in androgen-independent prostate cancer cell
linesrevealsthatitmaycontributetothemoreaggressivephenotype
of androgen-independent prostate carcinomas [19].
To evaluate target gene functions, we annotated these predicated
miRNA targets with gene ontology (GO) and KEGG schemes using
DAVID. Predicted miRNA targets populated many major GO
categories, and for some of them, the number of gene targets was
significantly enriched (P,0.001, with Benjamini correction). The
three GO classifications, molecular function, biological process and
cellular componentwere evaluated bylevel,butonlysignificant terms
at level 5 of biological process are listed in Table S3. As expected,
most of the significant GO terms were related to regulation of
transcription (e.g. GO:0045449, GO:0006351 and GO:0006357).
There are also a number of significantly enriched GO categories,
including cell morphogenesis (GO:0000902), intracellular transport
(GO:0046907), and apoptosis (GO:0006915). To analyze the role
Table 1. Top 20 miRNAs differentially expressed between the
LNCaP and LNCaP-AI libraries.
miRNA ID Relative count P-value
Fold
change
LNCaP LNCaP-AI
hsa-miR-222 290.95 5977.41 0 20.54
hsa-miR-124 15.02 219.24 5.93E-127 14.59
hsa-miR-30a* 3.46 42.02 3.84E-24 12.11
hsa-miR-100 12.71 114.53 6.86E-57 9.01
hsa-miR-30c-2* 8.09 65.40 1.29E-31 8.08
hsa-miR-30a 17.34 135.20 1.04E-62 7.80
hsa-miR-10b 1.54 11.52 2.31E-06 7.47
hsa-miR-296-3p 4.62 34.22 1.58E-16 7.40
hsa-miR-629 2.31 16.94 9.28E-09 7.33
hsa-miR-148b 18.49 132.83 3.46E-59 7.18
hsa-miR-760 10.02 66.08 6.76E-29 6.59
hsa-miR-1323 37.38 205.69 1.22E-77 5.50
hsa-miR-200b 284.02 51.84 1.09E-109 5.48
hsa-miR-96* 16.18 2.37 1.83E-08 6.82
hsa-miR-106a 11.95 1.69 1.19E-06 7.05
hsa-miR-362-5p 11.18 1.36 1.06E-06 8.25
hsa-miR-301b 13.11 1.36 4.15E-08 9.67
hsa-miR-1277 45.47 4.41 1.09E-25 10.32
hsa-miR-664 18.50 1.00 3.72E-15 18.50
hsa-miR-301a 75.15 3.05 2.34E-52 24.64
doi:10.1371/journal.pone.0015519.t001
Figure 3. The miRNAs expression level and validation of the robust of Solexa sequencing with qRT-PCR analysis. (A) Expression level
of LNCaP and LNCaP-AI miRNAs. The count of each miRNA was plotted after normalization. Red color circle shows differentially expressed miRNAs
between LNCaP and LNCaP-AI with at least a 2-fold change and p-value below 0.001. (B) Solexa vs. qRT-PCR of miRNA fold-changes.
doi:10.1371/journal.pone.0015519.g003
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miRNA targets into KEGGpathways,and identified 14 of them were
significantly enriched (P,0.001, with Benjamini correction). Most of
these miRNAs tend to target genes involved in signal transduction
and cell communication (Table S4). For example, we found that 130
target genes (2.3%) could be assigned to the MAPK signaling
pathway, which is involved in a wide range of cellular responses,
including gene expression, differentiation, proliferation and apoptosis
[20]. In prostate cancer, MAPK signaling pathways are generally
considered to promote tumor growth and the emergence of
hormone-refractory disease [21,22,23].
Discussion
In this study, we have identified a large set of miRNAs that are
differentially expressed underlying the progression of androgen-
independent prostate cancer, which were also verified by qRT-
PCR. Some of these miRNAs are well supported by recently
published studies. A striking example comes from the over-
expression of miR-221 and miR-222 in the LNCaP-AI sample by
a 10-20 fold increase, where both of them are among the most
abundant miRNAs in the LNCaP-AI cell line. Overexpression of
miR-221 or miR-222 in LNCaP could significantly reduce the
level of the dihydrotestosterone induced up-regulation of prostate-
specific antigen expression and increase androgen-independent
growth of LNCaP cells [9]. Several lines of evidence suggested that
miR-221 and miR-222 could down-regulate the tumor suppressor
p27 in LNCaP cells, and their overexpression might be one of the
factors contributing to the progression of prostate carcinoma [24].
Moreover, increased expression of miR-125b, miR-30c, miR-100
that we observed in LNCaP-AI cell lines was also identified to be
up-regulated in five AI CaP cell lines [25], and in vitro experiment
showed that miR-125b could stimulate the AI growth and down-
regulate the expression of BaK1 [25]. The reduction of miR-141,
miR-19b, miR-22, miR-29a, and miR-29b identified here was also
noted among the 15 miRNAs that were decreased in four
hormone-refractory prostate carcinomas as described in Porkka et
al.’s microarray-based study [26].
We also identified a set of differentially expressed miRNAs,
which has not been documented in prostate tumorigenesis or AI
development. For example, miR-124, miR-148b, miR-320a and
miR-423-5p were up-regulated by 2 to 14-fold, while miR-29a,
miR-93, miR-200 and miR-1277 were down-regulated by 2 to 10-
fold, suggesting that these miRNAs could exert a role as tumour
suppressor genes or oncogenes in prostate cancer development. It
is of interest to note that all five members of the miRNA-200
family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429)
were significantly down-regulated in LNCaP-AI cells. All these
miRNAs were also identified to be down-expressed in cells that
had undergone epithelial to mesenchymal transition [27], which is
viewed as an essential early step for progression of non-invasive
tumor cells into metastatic carcinomas [28]. Targets of these
microRNAs were found to be E-cadherin transcriptional repres-
sors ZEB1 and SIP1, factors previously implicated in tumour
metastasis [27]. A most recent study revealed that ZEB1
expression could enhance transendothelial migration in prostate
cancer cells [29]. Taken together, these findings indicate down-
regulation of the miR-200 family may also contribute to the
progression of prostate cancer.
Genome-wide miRNA expression profiling will undoubtedly
enhance our understanding of miRNAs and their roles in the
process of tumor invasion and metastasis [1,2]. However, the effort
of depicting a clear microRNA profile in prostate cancer is not that
conclusive and different studies may give opposite expression of
some microRNAs in prostate cancer [4,8]. Such discrepancies may
be due to the application of different profiling methods (e.g.
microarray, sequencing, qRT-PCR), specimen collection, miRNA
preparation, or analytical tools. Notably, certain miRNAs may act
as either oncogenes or tumor suppressors in different contexts, and
thus may lead to conflicting expression profiles [30]. In this study,
both the direct sequencing and qRT-PCR assays indicated that
miR-29a was significantly down-regulated by 2.8-fold in the
LNCaP-AI cell line as compared to in the LNCaP cell line. Similar
patterns were also found in haematopoietic, cholangiocytic and
lung tumours [31,32,33], whereas in breast carcinomas miR-21a
was over-regulated [30]. Hence it is important to interpret miRNA
transcriptome results with caution.
In sum, we have investigated the miRNA expression profiles in
human prostate cancer using direct miRNA sequencing approach
and qRT-PCR. Unlike previous studies, we focused on how
miRNAs response to the development of androgen independence
in prostate cancer. We found a number of miRNAs were
significantly differentially expressed between two different pheno-
types of prostate cancer, and some of them are well consistent with
Table 2. The novel miRNAs validated by qRT-PCR.
miRNA ID Sequence
Length
(nt) Genomic location
59/39
arm
Precursor
length (nt) MFE Relative count
LNCaP LNCaP-AI
hsa-novel-miR-01* TCGGGCGGGAGTGGTGGCTTTT 22 chr6:28918819:28918903:+ 39 85 222.2 277.47 816.64
hsa-novel-miR-02* ACTGACAGGAGAGCATTTTGA 21 chr5:89312448:89312527: 2 39 80 239.3 0 45.41
hsa-novel-miR-03* TCTCAGGAGTAAAGACAGAGTT 22 chr11:70718384:70718464: 2 39 81 249.2 0 21.69
hsa-novel-miR-04* GCAAATGATGTGAGAGATTC 20 chr6:168343859:168343952:+ 39 94 220.2 0 11.52
hsa-novel-miR-05* AAAAGCTGGGTTGAGAGGGTAA 22 chr18:21901636:21901711:+ 39 76 232.6 4.62 11.18
hsa-novel-miR-06* ACTGGACTTGGAGTCAGAAGA 21 chr10:132760891:132760988: 2 39 98 234.9 10.02 10.17
hsa-novel-miR-07* TCTGATGATGATGATGGTGCT 21 chr15:89826590:89826677:+ 59 88 218.2 24.66 0
hsa-novel-miR-08* CAAAATGATGAGGTACCTGATA 22 chr20:3194751:3194835:+ 59 85 220.4 73.22 0
hsa-novel-miR-09 ACCCCAGGATGCCAGCATAGTT 22 chr5:138611933:138612022:+ 59 90 232.2 19.65 0
hsa-novel-miR-10 TAGCTCTGATGATGGTGGTTTCT 23 chr5:176878879:176878970: 2 39 92 223.2 11.18 0
*indicates that the miRNA has been successfully validated by qRT-PCR. MFE refers to the minimum free energy.
doi:10.1371/journal.pone.0015519.t002
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lines is not necessarily the same as clinical samples, we believe that
the differentially expressed miRNA identified in this study would
provide good candidates for further functional evaluation.
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